BAB V KESIMPULAN DAN SARAN
B. Saran
Berdasarkan hasil dan pembahasan yang telah diuraikan sebelumnya, maka peneliti memberikan saran antara lain sebagai berikut : 1. Perlu adanya penelitian lebih lanjut dengan jumlah sampel yang lebih
banyak, kriteria inklusi dan kriteria ekslusi lebih spesifik agar lebih homogen, serta memperhatikan variabel-variabel pengganggu yang dapat menimbulkan bias pada hasil penelitian sehingga dapat memberikan gambaran yang lebih baik dan lebih bermakna
2. Sebaiknya pada penelitian selanjutnya hasil pemeriksaan immunohistokimia dengan hasil HER-2 “+2” dilakukan pemeriksaan lebih lanjut untuk konfirmasi agar sampel yang didapatkan lebih banyak. 3. Sebaiknya pada administrasi hasil laboratorium patologi anatomi harus
60
ada peneltian yang ingin membahas ini akan mempermudah dari peneliti untuk mendata.
61
DAFTAR PUSTAKA
American Joint Committee (2009). Diakses 21 Maret, 2016, from
https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf.
((RSKD), R. (2002). Pentalaksanaan Kanker Payudara Terkini/Tim Penanggulangan & Pelayanan Kanker Payudara Terpadu Paripurna (1st ed., Vol. I). Jakarta: Pustaka Populer Obor.
American Joint Committee on Cancer 7th. (2010). Breast Cancer Staging 7th ed. Retrieved April 2, 2016, from https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf
Aryandono. (2006). Semakin Tinggi Penderita Kanker Payudara di Usia Muda. Retrieved Maret 20, 2016, from http://ugm.ac.id/id/berita/1811-semakin.tinggi.penderita.kanker.payudara.di.usia.muda
Ayadi, L., & Khabir, A. (2008). Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian Breast Carcinoma, 112. Retrieved from http://www.wjso.com
Ayadi, L., & Khabir, A. (2008). Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World Journal of Surgical Oncology.
Bouchbika, Z., Benchakroun, N., & Taleb, A. (2012). Association between Overexpression of HER-2 and Other Clinicopathologic Prognostic Factors in Breast Cancer in Morocco.
Cho. (n.d.). Structure of the extracelull
ar region of HER2 alone and in complex with the Herceptin Fab. 2003.
CL, C., & LC, C. (2005). Molecular Targets in Oncology: Signal Transduction System (VII ed.). Lippincot-Raven.
Committee, A. J. (2009). Retrieved Maret 21, 2016, from
62
Curigliano, G., & Viale, G. (2009). Clinical Relevance of HER-2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. Journal of Clinical Oncology.
DiLeo., D. M.-L. (2002). Current status of HER-2 testing, 25-32.
Fan, Y. X. (2008). Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. 1588-1596.
Farzami, M., Anjarani, S., & Safadel, N. (2008). Association between the expression of homone receptors, HER-2/neu overexpression and tumor characteristics in women with primary breast cancer. The Internet Journal of Pathology Volume 8 Number 2.
Gautam K. Malhotra, X. Z. (2010). Histological, Molecular and Functional Subtypes. 956.
Globocan. (2012). Cancer Fact Sheets. Retrieved Maret 20, 2016, from http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
GLOBOCAN. (2012). International Agency for Reasearch on Cancer. Retrieved March 23, 2015, from GLOBOCAN 2012 IARC: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
Gray, M., & Gallick, G. (2010). The role of oncogene activation in tumor progression, 19-22.
Greulich, H. K. (2012). Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. U. S. A.
Grushko, T., & Olopaeda, O. (2008). Genetic Markers in Breast Tumors With Hereditary Predisposition, 85-93.
Harris, L., Fritsche, H., & Mennel, R. (2007). Journal of Clinical Oncology. Update of Recommendation for the Use of Tumor Marker in Breast Cancer, 25. Retrieved April 4, 2016, from http://www.jco.ascopubs.org
Institute, N. C. (2015). What is cancer ? Retrieved Maret 20, 2016, from http://www.cancer.gov/cancertopics/what-is-cancer.
Junquera, L., & Carneiro, J. (2007). Histologi Dasar Teks dan Atlas (10th ed.). Jakarta: EGC.
Kamarlis, R. K. (2009). Tampilan Imunohistokimia HER-2/neu Pada Biopsi Aspirasi Jarum Halus Penderita Kanker Payudara, 45-48.
KPKN, K. (2015). Panduan Nasional Pembangunan Kanker Payudara. Retrieved
Maret 20, 2016, from
https://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf
Kresna, S. B. (2014). Biomarker Keganasan (1st ed.). Jakarta: Badan Penerbit FKUI.
Kumar, V. A. (2015). Robbins and Kontran Pathologic Basic of Disease (9th ed.). Philadelphia: Elsevier Saunders.
Lee. (2006). Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
Lina, M. (2004). Kanker pada Wanita: Pencegahan dan Pengobatan dengan Tanaman Obat. Jakarta: Penebar Swadaya.
Mahir, W., Rouss, L., & Ouzir, M. (2016). Correlation of ER, PR, and HER-2 with clinico-pathological parameters in infiltrating Ductal Carcinoma of Breast in Morocco.
Maimun, M. (2013). Payudarapedia. Retrieved from Anatomi dan Fisiologi Payudara: http://payudarapedia.blogspot.co.id/2013/05/anatomi-dan-fisiologi-payudara.html
Mane, A. (2015). A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Woman, 1.
Mary, C., & Lori J., G. (2016). Prognostic and Predictive Factors in Early-Stage
Breast Cancer. Retrieved April 4, 2016, from
http://theoncologist.alphamedpress.org/content/9/6/606.full
Moonkhouse, S. (2007). Clinical Anatomy (2nd ed.). China: Churchill Livingstone Elsevier.
64
Notoatmodjo, S. (2010). Metodologi Penelitian Kesehatan. Jakarta: Rineka Cipta. NPD, W. (2014). In Situ Hybridization pada Kanker Payudara. Retrieved from
http://journal.uii.ac.id/index.php/JKKI/article/view/3392/3041
Otto, S. (2001). Oncology Nursing (4th ed.). Mosby years book.
Payne, S., Bowen, R., Jones, J., & Wells, C. (2008). Predictive Marker in Breast Cancer The Present, 82-90.
Pedersen. (2009). A naturally occuring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.
Price, S., & Wilson, L. (2005). Patofisiologi Konsep Klinis Proses-Proses Penyakit. Jakarta: EGC.
Pringguoutomo, S., Himawan, S., & Tjarta, A. (2002). Buku Ajar Patologi I (UMUM) (1st ed.). Jakarta: Sagung Seto.
Rahman, A. (2014). Hubungan Ekspresi HER-2/neu dan Hormonal Reseptor Dengan Grading Histopatologi Pada Penderita Kanker Payudara Wanita Usia Muda.
Ramli, M., Umbas, R., & Panigoro, S. (2000). Deteksi Dini Kanker.
RI, P. D. (2015). Retrieved Maret 20, 2016, from http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodati n-kanker.pdf.
Sabiston, A. (2011). Buku Ajar Bedah I. Jakarta: EGC.
Sastroasmoro, S., & Ismael, S. (2011). Dasar-Dasar Metodologi Penelitian Klinis (4th ed.). Jakarta: Sagung Seto.
Sjamsuhidajat, R., & de Jong, W. (2010). Buku Ajar Ilmu Bedah. Jakarta: EGC.
Stephens, P. H. (2004). intragenic ERBB2 kinase mutations in tumors. Lung cancer, 525-526.
Tanto, C., L., F., & H., S. (2014). Kapita Selekta Kedokteran. Jakarta: Media Aesculapius.
Tjahdadi, V. (2008). Kanker Payudara. Retrieved Maret 20, 2016, from http://bima.ipb.ac.id/~anita/kanker_payudara.htm
UNDIP, T. K. (2006). Kanker Payudara Wanita. Ekspresi Reseptor Estrogen, Reseptor Progesteron dan HER-2. Retrieved Maret 24, 2016, from www.m3undip.org/ed3/artikel_t
Wahid, S., Miskad, U. A., & Djimahit, T. (2008). Ekspresi HER-2/neu pada Kanker Payudara. Korelasi Bermakna Dengan Grading Histopatologi. Retrieved
Maret 20, 2016, from
http://www.med.unhas.ac.id/journal/dmdocuments/journal 2008
Wan, D. (2011). Buku Ajar Onkologi Klinis (2nd ed.). Jakarta: Balai Penerbit FK UI.
WHO. (2013). Cancer Fact Sheet. Retrieved Maret 20, 2016, from http://www.searo.who.int/entity/noncommunicable_diseases/advocacy/ca ncer_fact_sheet.pdf?ua=1.
William, H. (2004). Profil Gena HER-2/neu pada Penderita Kanker Payudara di Makassar.
World Health Organization. (2015). World Health Organization. Retrieved March 17, 2015, from World Health Organization: http://www.who.int/cancer/detection/breastcancer/en/
66
LAMPIRAN
LAMPIRAN 1. Analisis Statistik
Analisis Karakteristik Subjek Penelitian Berdasarkan Usia
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
68
Analisis Karakteristik Subjek Penelitian Berdasarkan Ukuran Tumor T1 dan T2 dengan T3
70
Analisis Karakteristik Subjek Penelitian Berdasarkan Ukuran Tumor T1 dengan T2 dan T3
72